Drug intelligence / Profile preview

sisunatovir

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Sisunatovir is an orally administered, small molecule inhibitor developed for the treatment of respiratory syncytial virus (RSV) infections. It specifically targets and binds to the RSV fusion (F) protein on the viral surface, inhibiting F protein-mediated fusion with host cell membranes and thereby preventing viral entry into cells. This mechanism blocks RSV replication, reduces viral load, and decreases disease severity. Sisunatovir has been investigated in clinical trials for use in infants, children, immunocompromised patients, and older adults at risk of severe RSV infection. The drug was originally developed by ReViral and is now being advanced by Pfizer following acquisition[1][3][4][5][6][7].

Other names: 1903763-82-5

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on sisunatovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sisunatovir.

Explore the full profile